Duvelisib 治疗复发/难治性外周 T 细胞淋巴瘤:II 期 PRIMO 试验最终结果
PRIMO 是一项全球多中心 II 期试验,评估 Duvelisib 单药治疗复发/难治性外周 T 细胞淋巴瘤(PTCL)。PRIMO-EP 队列(N=123)客观缓解率 48.0%,完全缓解率 33.3%,中位无进展生存期 3.4 个月,中位总生存期 12.4 个月;血管免疫母细胞性 T 细胞淋巴瘤(AITL)亚组疗效更突出,ORR 62.2%,CRR 51.4%。
要点
- Duvelisib 在 R/R PTCL 中客观缓解率 48.0%,完全缓解率 33.3%。
- AITL 亚组 ORR 62.2%、CRR 51.4%,中位 PFS 8.3 个月。
- ≥3 级治疗中出现的不良事件发生率为 74.0%。
核心结论
- PRIMO 研究显示 Duvelisib 在 R/R PTCL 中具有显著活性和可耐受性,尤其在 AITL 亚组。
研究设计与样本
- PRIMO 为 II 期试验,分剂量优化和剂量扩展(PRIMO-EP)两阶段,在全球 45 个中心开展。
- PRIMO-EP 纳入 123 例 ≥18 岁、组织学确诊 PTCL 且接受过至少 2 周期标准方案的患者。
- PRIMO-EP 采用 75 mg 每日两次用 2 周期后改为 25 mg 每日两次,持续至疾病进展或不可耐受毒性。
主要发现
- PRIMO-EP(N=123)独立评审委员会评估的 ORR 为 48.0%,CRR 为 33.3%。
- PRIMO-EP 中位 PFS 为 3.4 个月,中位 OS 为 12.4 个月,中位 DOR 为 7.9 个月。
- AITL 亚组 ORR 为 62.2%,CRR 为 51.4%,中位 PFS 为 8.3 个月,中位 OS 为 18.1 个月,中位 DOR 为 11.3 个月。
- 任何级别 TEAE 发生于 120 例(97.6%),≥3 级 TEAE 发生于 91 例(74.0%)。
- 导致暂停给药或减量的 TEAE 分别发生于 44.7% 和 9.8% 的患者。
临床怎么用
- Duvelisib 单药可作为 R/R PTCL 的治疗选择,尤其对 AITL 亚组疗效更突出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Peripheral T-cell lymphomas (PTCLs) are rare, heterogeneous, aggressive lymphomas. Five-year overall survival (OS) remains approximately 30%-40%, and most patients will develop relapsed or refractory (R/R) disease. Duvelisib is an oral dual inhibitor of phosphatidylinositol 3-kinase (PI3K)-δ and PI3K-γ isoforms. Here, we report on the final analysis of the phase II PRIMO trial (ClinicalTrials.gov identifier: NCT03372057; Secura Bio, Inc) evaluating duvelisib monotherapy in R/R PTCL. METHODS: PRIMO was conducted in two phases (dose optimization and dose expansion [PRIMO-EP]) at 45 centers globally. Eligible patients were age 18 years and older, had histologically confirmed diagnosis of PTCL, and had received ≥2 cycles of one standard regimen for PTCL. Based on dose optimization results, the selected regimen for PRIMO-EP was 75 mg twice a day for two cycles (to maximize disease control) followed by 25 mg twice a day (to reduce late toxicities), continued until progressive disease or unacceptable toxicity. RESULTS: PRIMO-EP (N = 123) outcomes included independent review committee-assessed objective response rate (ORR): 48.0%, complete response rate (CRR): 33.3%, median progression-free survival (mPFS): 3.4 months, median OS (mOS): 12.4 months, and median duration of response (mDOR): 7.9 months. In the angioimmunoblastic T-cell lymphoma (AITL) subgroup, outcomes were ORR: 62.2%, CRR: 51.4%, mPFS: 8.3 months, mOS: 18.1 months, and mDOR: 11.3 months. Treatment-emergent adverse events (TEAEs; any grade) occurred in 120 patients (97.6%), and TEAEs grade ≥3 occurred in 91 patients (74.0%). TEAEs resulting in dose hold or dose reduction occurred in 44.7% and 9.8% of patients, respectively. CONCLUSION: The PRIMO study demonstrates significant activity and tolerability of duvelisib in patients with R/R PTCL, most notably in the AITL subgroup. This provides strong rationale for further development in PTCL, and more specifically in the subgroup of nodal T-follicular helper cell lymphoma.
引用
- Mehta-Shah N, Zinzani PL, Jacobsen ED, et al. Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2026. PMID: 42018969. doi:10.1200/JCO-25-03120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。